周三早盘，现货黄金向上触及5150美元，现货白银向上触及87美元/盎司，日内上涨0.2%。 | 名称 | 现价 | 涨跌 | 涨跌幅 | 年初至今 | | --- | --- | --- | --- | --- | | 伦敦金现 | 5150.700 | 18.690 | 0.36% | 19.28% | | 伦敦银现 | 87.307 | 0.219 | 0.25% | 21.98% | | COMEX黄金 | 5152.8d | -23.5 | -0.45% | 18.14% | | COMEX白银 | 86.840d | -0.666 | -0.76% | 22.34% | 消息面上，据央视新闻报道，美国对俄罗斯与阿联酋的个人和实体实施制裁。当地时间2月24日，美国财政部海外资产控制办公室宣布，根据 《以制裁反击美国敌人法》(CAATSA)及网络相关制裁措施，将4名个人和3家实体列入"特别指定国民"名单，涉及俄罗斯及阿联酋。根据公 告，被制裁对象在美国境内的资产及资产权益将被冻结，美国公民和机构被禁止与其进行交易。部分实体还面临额外限制，包括禁止美国金融 机构提供超过规定金额的贷款、限制外汇交易及禁止美 ...

Regulatory Updates - The National Medical Products Administration (NMPA) has released the "Guidelines for Pharmaceutical Research on Chemical Drugs for Rare Diseases (Trial)" to enhance support for rare disease drug development and improve technical guidance principles [1] - Hengrui Medicine's innovative drug SHR-1918 injection has been accepted for priority review by the NMPA, aimed at treating patients with homozygous familial hypercholesterolemia [1] - CanSino Biologics has expanded the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, which is expected to positively impact the company's performance [2] - Tongrentang Pharmaceutical has received product registration approval from Health Canada for several products, including children's cough syrup, although further administrative approvals are required for sales [3] - Shanghai Pharmaceuticals has obtained a drug registration certificate in Singapore for rivaroxaban tablets, which are used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients [4] - Baotai has received acceptance for the marketing authorization application of its drug BAT4406F, intended for treating adult patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder [5] Industry Developments - Zhejiang Medicine plans to invest 250 million yuan in a silver economy fund in collaboration with a private equity fund, focusing on the healthcare sector [6] - Zhijiang Biology has completed a strategic increase in its stake in Sanyou Biopharmaceuticals, enhancing its position in the precision medicine sector [7] - Xianweida Biopharmaceutical has entered a commercialization agreement with Pfizer China for its GLP-1 receptor agonist, which could yield up to $495 million in payments [8] Financial Performance - Sangfor Technologies reported a projected net profit increase of 317.09% for 2025, driven by a significant collaboration with Pfizer that resulted in a revenue recognition of approximately 2.89 billion yuan [9] Capital Market Activities - Duorui Pharmaceuticals announced a stock suspension following the expiration of a tender offer period, pending confirmation of the offer results [10] - Jiutian Pharmaceutical completed a share buyback of 1.24% of its total shares, with a total transaction amount of 100 million yuan [11] - Shenlian Biopharmaceutical plans to acquire controlling interest in Shiziyuan Biotechnology for 237 million yuan, aiming to expand into innovative drug business [12]

Core Viewpoint - The promotion of a comprehensive green and low-carbon transformation in the economy and society has become a crucial task for local development, with a focus on the establishment of a "building carbon credit mechanism" to enhance the value of emission reduction effects in green buildings [1] Group 1: Current Situation and Challenges - China's construction sector accounts for approximately 40% of the country's total carbon emissions, with public building operation emissions contributing about 9% [1] - The highly decentralized nature of carbon emissions in the construction sector makes it difficult to incorporate them into mandatory quota management, and the complexity of emission reduction data hampers real-time monitoring and precise measurement [1] - The limited economic value of individual voluntary emission reduction projects in the construction sector poses challenges in matching the high costs and implementation barriers of CCER development [1] Group 2: Initiatives and Developments - In 2023, Greenland Jinchuang, in collaboration with other institutions, launched the "building carbon credit mechanism" at the Guizhou Low Carbon Trading Center, which quantifies and certifies the greenhouse gas reduction effects of voluntary emission reduction projects in public buildings [2] - By the end of 2025, the Guizhou Low Carbon Trading Center has listed 11 domestic building carbon credit products, facilitating nearly 30,000 tons of public building carbon reduction to be recognized as tradable intangible assets on financial statements [2] - The trading of carbon credits is expected to generate approximately 1.5 million yuan in direct economic benefits for owners, based on a transaction average price of 54 yuan/ton from the previous year [2] Group 3: Recommendations for Development - It is recommended that the Shanghai government recognize the building carbon credit mechanism as a practical outcome supporting the national "dual carbon" strategy and promote it in pilot areas such as Baoshan District and Qingpu District [3] - The Shanghai government should support the Guizhou Low Carbon Trading Center in developing high-credibility methodologies and corresponding carbon credit products to enhance the service capacity of the voluntary emission reduction mechanism [3] - The recognition and expansion of the application of high-quality carbon credits from the Guizhou Low Carbon Trading Center into the Shanghai carbon market is suggested, allowing for carbon offsetting through the purchase of these credits [4] - Continuous exploration of international cooperation in energy conservation and carbon credit trading is recommended, leveraging previous experiences to enhance participation in the international carbon market [4]

此次大会内容丰富、亮点纷呈，将全方位展现天河高质量发展的丰硕成果。大会将以《一马当先看天河领跑湾区向未来》成果 展示短片拉开序幕，直观呈现天河领跑湾区的强劲活力。现场将聚焦广州国际金融城、广棠科创城、奥体体育城三大重点片区 进行专题推介，清晰释放未来发展规划与招商机遇。 人勤春来早，奋进正当时。紧随省、市高质量发展大会之后，2月26日，农历正月初十，广州天河区将召开全区高质量发展大 会，围绕"双核引领，工商并举，大区挑大梁"主题，凝聚全区力量开局即冲刺、全年都加力。站在7000亿的新起点，天河区将 以此次大会为契机，全面梳理发展成果、擘画未来蓝图，进一步释放以中央商务区与中央科创区"双核"为引领，推动先进制造 业与现代服务业深度协同的强劲信号，为广州率先基本实现社会主义现代化贡献天河力量，在大湾区高质量发展的浪潮中一马 当先、勇立潮头。 在全市高质量发展版图中，天河区以"排头兵、领头羊、火车头"的姿态勇挑大梁，已连续第四年在农历新年后召开全区"新春第 一会"，释放出坚持以实体经济为本，发挥工商并举优势，促进两业协同发展，全力建设现代化产业体系的强烈信号。据悉，大 会会期半天。南方财经"21财经"客户端将于2月 ...

但真正的功能性需求，其面对的是一个完全"非结构化"的世界。每一个家庭的布局、家具的摆放、成员 的行为逻辑，甚至是一顿晚餐的烹饪方式，都没有统一的标准可循。这意味着，人形机器人不能仅仅依 靠预设的程序来生存，它必须拥有极强的"泛化能力"和"具身智能"，能够通过视觉和传感器实时理解环 境，并根据突发状况做出逻辑判断。 当机器人离开光滑的舞台，踏上松软的地毯、避开随手乱丢的玩具、在狭窄的厨房里处理油腻的碗筷 时，原本在舞台上显得游刃有余的"大动作"将会面临巨大的考验。这种从"封闭实验室"到"开放社会"的 跨越，正是人形机器人当前面临的最高的一道门槛。 再从技术的角度来看，真正难的，往往不是大动作，而是精细动作。在春晚舞台上，我们看到了机器人 可以翻跟头、踢腿、快跑，这些动作考验的是大功率关节执行器、动态平衡算法以及结构强度，这可以 被视为"粗线条"的体育竞技。 回顾今年的马年春晚，最受瞩目的毫无疑问是满屏的国产人形机器人。它们不仅在央视及地方春晚舞台 上奉献了大规模、高难度的表演，更在我们身边的庙会、商场、餐厅等线下场景广泛应用。 在春晚舞台的聚光灯下，数十台机器人整齐划一地完成空翻、侧踢、变阵，甚至与人类演员进行 ...

2月23日，"史上最长春节假期"结束。交通运输部数据显示，春节假期期间，全社会跨区域人员流动量 累计超28亿人次，日均3.11亿人次，同比增长8.2%，出行规模创历史新高。其中，全国铁路累计发送旅 客1.21亿人次；民航累计发送旅客2205万人次。 文化和旅游部数据显示，春节假日9天，全国国内出游5.96亿人次，较2025年春节假日8天增加0.95亿人 次；国内出游总花费8034.83亿元，较2025年春节假日8天增加1264.81亿元。 假期多出1天，让2026年春节假期整体出游热度创历史新高。出外"旅游式过年"，与返乡"过年式旅 游"双双爆火，全国不仅各大知名景区人从众，"家门口旅游"也带火了县城里的景区，一批小城迎来了 始料未及的"泼天流量"。更多返乡过年的城里人，也把新的生活方式带进了村里，热门县城春节期间酒 店预订量翻倍增长。 出入境旅游也是双向火爆。泰国重回出境游榜首，冬奥会带动中国—意大利机票量增2倍；越来越多的 外国朋友来体验中式"年味儿"，春节期间使用非中国护照预订国内航班数量同比增长两成，足迹覆盖 107个中国城市。 传统民俗是"大菜" 过年不再围着饭桌转，而是主打舒服随心。陪爸妈city ...

周二（2月24日），美国三大股指全线收涨，道指、标普500指数涨超0.7%，纳指涨1%，全市场超3500股上涨。 | 道琼斯工业 | 纳斯达克指数 | 标普500 | | --- | --- | --- | | 49174.50 | 22863.68 | 6890.07 | | +370.44 +0.76% +236.41 +1.04% +52.32 +0.77% | | | | 美国科技七巨头 中概科技龙头 中国金龙 | | | | 63258.79 | 3993.74 | 7581.04 | | +675.29 +1.08% -19.84 -0.49% +102.63 +1.37% | | | | 道琼斯期货 | 纳斯达克100期 | 标普500期货 | | 49203 | 25016.25 | 6900.00 | | +354 +0.72% +253.50 +1.02% +48.50 +0.71% | | | 软件股回暖，汤森路透涨11.4%，SaaS龙头赛富时涨超4%，昨日重挫13%的IBM也反弹涨超2%。据智通财经报道，近期多次引发全球软件股抛售的AI明星 公司Anthropic在最新简报会上传递" ...

2月24日，农历马年第一个工作日，广东"新春第一会"连续第四年召开，再次奏响高质量发展时代强 音。今年广东高质量发展大会的主题是"制造业与服务业协同发展"，为广东全年经济发展打响持续争先 的"发令枪"。 广东省委书记黄坤明在大会上强调，推动制造业与服务业协同发展，是顺应产业演进规律、实现产业高 级化的必由之路，是拥抱科技浪潮、赢得未来主动的关键之举，是畅通经济循环、丰富群众生活的战略 之需。制造业与服务业双向奔赴，关乎广东高质量发展大局、现代化建设全局。 从产业科技互促双强到建设现代化产业体系，再到制造业与服务业协同发展，广东接下来如何在两业协 同中实现产业发展提质增效？如何以制造业之强牵引服务业之优，以服务业之优增进制造业之强， 在"制造强省"与"服务高地"相互成就中打开产业发展新天地？日前，南方财经记者专访了中山大学中国 第三产业研究中心主任、教授、博导李江帆，围绕上述问题展开深入探讨。 广东推动两业协同恰逢其时 南方财经：2026年广东省政府工作报告提出，分领域推进生产性服务业向专业化和价值链高端延伸，促 进生活性服务业高品质、多样化、便利化发展。你认为，广东生产性服务业在向专业化和价值链高端延 伸的过 ...

Core Viewpoint - The article emphasizes the urgent need for a comprehensive and sustainable support system for rare disease patients in China, highlighting the challenges they face in accessing necessary medications and treatments [1][10]. Policy Framework - The national policy framework for rare diseases is becoming clearer, with approximately 100 rare disease drugs included in the medical insurance directory by 2025, covering 42 disease types [2]. - Basic medical insurance is limited to addressing fundamental issues, indicating a need for a structured "second battlefield" to tackle high-value rare disease medications [2]. Patient Statistics - There are over 7,000 known rare diseases globally, affecting approximately 3.5% to 5.9% of the population, translating to 260 million to 450 million people worldwide [2]. - In China, around 1,400 rare diseases have been identified, with an estimated 20 million patients affected [2]. Case Study: Gaucher Disease - Gaucher disease serves as a key example of the challenges in medication access, with treatment costs reaching approximately 1 million RMB annually for patients [3]. - Shanghai has implemented a multi-channel support model since 2013, but the sustainability of this model is now in question due to potential discontinuation of funding [3]. Payment Models and Challenges - The DRG/DIP payment model creates financial disincentives for hospitals to treat rare disease patients, leading to a situation where patients struggle to access necessary care despite medications being covered by insurance [4]. - There are significant legal and systemic issues that need to be addressed to create a robust support system for rare disease medications and patient assistance [4]. Integration of Support Systems - The establishment of local rare disease special funds is seen as a necessary step to overcome fragmented policies and improve coordination among various support mechanisms [6]. - A comprehensive "1+N" model for rare disease support is emerging, integrating personal payments, special insurance, charitable donations, and national medical insurance [5]. Long-term Sustainability - Continuous medication is crucial for conditions like Gaucher disease, where treatment interruption can lead to irreversible damage, underscoring the need for stable and sustainable funding mechanisms [7]. - The proposed special funds aim to clarify application processes and share financial burdens among various support channels, addressing gaps in coverage for rare disease medications [7]. Local Initiatives - Local governments, such as Jiangsu Province, are developing provincial-level rare disease medication support mechanisms, which include specific diseases and treatment options [9]. - The Shanghai Rare Disease Relief Foundation has been instrumental in providing support and coordinating resources for patients, highlighting the importance of integrating various assistance programs [9]. Conclusion - The establishment of local rare disease special funds is not a rejection of existing systems but rather an enhancement of their capabilities, aiming to ensure that patients can access necessary medications and treatments consistently [10].

Core Viewpoint - Gude Electric Materials (301680.SZ) is set to be available for subscription on the ChiNext board, focusing on the research, production, and sales of components for thermal runaway protection in new energy vehicle (NEV) power batteries and electrical insulation products. The company is recognized as a leading player in the thermal runaway protection sector, crucial for NEV safety, with significant technological advancements and multiple national and provincial recognitions [1][2]. Group 1: Company Overview - Gude Electric Materials specializes in thermal runaway protection components for NEV power batteries and electrical insulation products [1]. - The company has received various accolades, including being recognized as a provincial enterprise technology center in Jiangsu in 2021 and a national "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology in 2022 [1]. - As of mid-2025, Gude Electric Materials holds 96 patents, including 36 invention patents and 60 utility model patents [1]. Group 2: Client Relationships - The company has established long-term stable partnerships with several global automotive manufacturers and battery producers, including General Motors, Ford, Stellantis, Tesla, Hyundai-Kia, Toyota, BMW, Geely, Leap Motor, Xpeng, and FAW Group [2]. - Gude Electric Materials has received high recognition from its clients, winning awards such as the "2024 Supplier Quality Excellence Award" from General Motors and "Best Service Supplier of 2024" from Geely Group [2]. Group 3: Financial Performance and Risks - The company's sales revenue from thermal runaway protection products exported to the U.S. from 2022 to mid-2025 were 0.51 billion, 1.13 billion, 2.25 billion, and 0.71 billion yuan, accounting for 10.80%, 17.38%, 24.73%, and 15.44% of total revenue, respectively [2]. - Gude Electric Materials faces trade policy risks, particularly due to fluctuating U.S. tariff policies, which could impact the growth rate of overseas sales and profit margins [2].